Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
24 hedge funds and large institutions have $34.1M invested in Zynerba Pharmaceuticals, Inc in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$14.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.9M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.75M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$3.84M |
Top Sellers
ZYNE Hedge Fund Activity: Q3 2015 in Review
24 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2015, worth a combined $34.1M.
Buyers outnumbered sellers: 24 funds opened new ZYNE positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $14.2M.
- 24 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $34.1M of Zynerba Pharmaceuticals, Inc stock for Q3 2015.
- 24 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2015 and 0 closed out, a net change of +24 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2015 was Perceptive Advisors, an estimated $14.2M added.
Based on aggregated 13F filings for Q3 2015.